Avanzanite Bioscience Expands UK Operations, Appoints Sarah O’Connell as Country Manager to Strengthen Rare Disease Medicine Access Avanzanite Bioscience B.V., a European pharmaceutical company specializing in rare diseases, has announced…
Laxxon Medical Appoints Matthew Cascio as Vice President and Head of Business Development to Drive Strategic Partnerships Laxxon Medical has announced the appointment of Matthew Cascio as Vice President and…
Powerful Medical Secures New CPT Code for Queen of Hearts AI ECG Technology to Detect Heart Attacks Powerful Medical, a company specializing in artificial intelligence (AI)-driven cardiovascular diagnostics, has announced…
Rumi Therapeutics Secures Option to License Enthorin’s IND-Ready PDE2 Inhibitor for Fragile X Syndrome Rumi Therapeutics, a drug-development company operating within Rumi Scientific Holdings, has announced an option-to-license agreement with…
Merck’s Sacituzumab Tirumotecan Cuts Risk of Death by 32% in Advanced Endometrial Cancer in Phase 3 TroFuse-005 Trial Merck, known as MSD outside the United States and Canada, has announced…
Incyte Presents Updated Clinical Data for KRAS G12D and TGFβR2×PD-1 Programs in Pancreatic and Colorectal Cancers Incyte has announced new clinical findings from its expanding oncology portfolio, highlighting the potential…
Dong-A ST Presents Preclinical Findings Supporting Topical Icotrokinra Development for Psoriasis Dong-A ST Co., Ltd., a South Korean pharmaceutical company led by President and CEO Jae-hoon Jeong, has presented preclinical…
Align Technology Commits $1 Million to AAO Foundation to Support Future Orthodontic Educators Align Technology, Inc., a global medical device company specializing in digital orthodontics and restorative dentistry, has announced…
NaphCare to Host Annual TechCare User Group to Advance Correctional Healthcare Technology and Innovation NaphCare, a provider of healthcare services for correctional facilities, will bring together correctional healthcare partners from…
PharmaEssentia to Present Preclinical Data on PEC2001 and PEC3001 Solid Tumor Immunotherapy Candidates at SITC 2026 PharmaEssentia Innovation Research Center (PIRC), a subsidiary of PharmaEssentia Corporation (TWSE: 6446), has announced…
HeartBeam’s 3D ECG Technology Accepted into FDA’s TAP Program to Advance Heart Attack Assessment HeartBeam, Inc., a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced…
GondolaBio Partners with Children’s Tumor Foundation to Advance Preclinical NF1 Drug Development Program GondolaBio, a clinical-stage biopharmaceutical company focused on developing innovative medicines for people living with genetic diseases, has…